What is the best approach for trans-arterial therapy in HCC?

Dr Alexander Kim is the chief of vascular and interventional radiology at Medstar Georgetown University Hospital. After graduating medical school at Drexel University College of Medicine he completed his residency and fellowship at Georgetown University Hospital. Dr Kim specializes in the treatment of hepatocellular carcinoma and is the national PI for the QED trial, a multi-center randomized, controlled trial on TACE for HCC. He also leads several other clinical trials on liver-directed therapies for primary and secondary liver cancers. Relevant publications Janowski E, Timofeeva O, Chasovskikh S, Goldberg M, Kim A, Banovac F, Pang D, Dritschilo A, Unger K. Yttrium-90 radioembolization for colorectal cancer liver metastases in KRAS and wild-type and mutant patients: Clinical and ccfDNA studies. Oncol Rep Dec 2016; 37(1): 57-65 Doi: 10.3892/or.2016.5284 PMID: 28004119 Kim AY, Unger K, Wang HK, Pishvain MJ. Incorporating Yttrium-90 trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcinoma: a single center experience. BMC Cancer 2016; 16 (1) :492. Doi: 10.1186/s12885-016-2552-2. PubMed PMID: 27430276 Kim AY, Miller A. Evaluation of Surefire’s precision direct-to-tumor embolization device to augment therapeutic response to intra-arterial liver-directed therapies for patients with primary and secondary liver cancers. Expert Rev Med Devices 2016 Mar 25:1-9. PubMed PMID: 26959530 Gabrielson A, Miller A, Banovac F, Kim A, He AR, Unger K. Outcomes and predictors of toxicity after selective internal radiation therapy using Yttrium-90 resin microspheres for unresectable hepatocellular carcinoma. Front Oncol 2015 Dec 23; 5:292. Doi: 10.2289/fonc.2015.00292. PubMed PMID: 26779437; PubMed Central PMCID: PMC4688348 Ertreo M, Caridi T, Buckley D, Lynskey G, Kim A. Long-term outcomes of Surefire Infusion System for DEB-TACE for HCC. JVIR 2017 Feb 28(2); S156-S157 Katrivesis J, Yoon J, Lynskey G, Buckley D, Caridi T, Kim A. Effect of tumor burden on contralateral lobar hypertrophy after portal vein embolization. JVIR 2017 Feb; 28(2): S18